


# INTERCEPT<sup>®</sup> Blood System for Platelets Pathogen Reduction System

## Targeting DNA and RNA to Prevent Pathogen Proliferation.

### A proactive approach to blood safety through reduction of a broad range of pathogens

The INTERCEPT System uses amotosalen - a well characterized photoactive compound that specifically targets DNA and RNA - and UVA illumination to irreversibly cross-link nucleic acids. In doing so, the INTERCEPT treatment blocks replication of viruses, bacteria, and parasites, rendering them inactive.<sup>1</sup>



## Broad Spectrum Pathogen Reduction

The INTERCEPT Blood System is a proactive approach to reducing transfusion-transmitted infectious (TTI) risk through the broad spectrum inactivation of viruses, bacteria, parasites, and leukocytes that can be found in platelet components. Robust inactivation is achieved, with  $\geq 4$  log reduction for most clinically relevant pathogens when using the INTERCEPT System.<sup>2</sup>

\* pathogen reduced Amicus apheresis platelets in PAS-3  
◇ pathogen reduced Trima apheresis platelets in 100% plasma

<b>Bacteria</b> Gram Negative, Gram Positive, Spirochetes
<i>Klebsiella pneumoniae</i> *◇
<i>Yersinia enterocolitica</i> *◇
<i>Escherichia coli</i> *◇
<i>Pseudomonas aeruginosa</i> *◇
<i>Salmonella choleraesuis</i> *◇
<i>Enterobacter cloacae</i> *◇
<i>Serratia marcescens</i> *◇
<i>Staphylococcus epidermidis</i> *◇
<i>Staphylococcus aureus</i> *◇
<i>Streptococcus pyogenes</i> *◇
<i>Listeria monocytogenes</i> *◇
<i>Corynebacterium minutissimum</i> *◇
<i>Bacillus cereus (vegetative)</i> *◇
<i>Lactobacillus species</i> *◇
<i>Bifidobacterium adolescentis</i> *
<i>Propionibacterium acnes</i> *◇
<i>Clostridium perfringens (vegetative)</i> *◇
<i>Treponema pallidum</i> *◇
<i>Borrelia burgdorferi</i> *◇

<b>Viruses</b> Enveloped, Non-enveloped
HIV-1 (cell associated) *◇
HTLV-I *
HTLV-II *
CMV *
WNV *◇
DHBV (model for HBV) *◇
BVDV (model for HCV) *◇
Pseudorabies (model for CMV) ◇
Chikungunya *◇
Dengue *◇
Influenza A *
Bluetongue virus *◇
Adenovirus *◇
<b>Protozoa</b>
<i>Trypanosoma cruzi</i> *◇
<i>Plasmodium falciparum</i> *◇
<i>Babesia microti</i> *◇
<b>T-Cells/ Leukocytes</b>
T-Cells*◇

## References

- 1) Wollowitz, S. Seminars in Hematology, 2001. 38 (Suppl 11): p. 4-11.
- 2) The INTERCEPT Blood System for Platelets Package Insert, Cerus Corporation; July 17, 2018.

## Contraindications<sup>2</sup>

Contraindicated for preparation of platelet components intended for patients with a history of hypersensitivity reaction to amotosalen or other psoralens. Contraindicated for preparation of platelet components intended for neonatal patients treated with phototherapy devices that emit a peak energy wavelength less than 425 nm, or have a lower bound of the emission bandwidth <375 nm, due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen.

## Warnings and Precautions<sup>2</sup>

Only INTERCEPT Processing Sets for platelets are approved for use in the INTERCEPT Blood System. Use only the INT100 Illuminator for UVA illumination of amotosalen-treated platelet components. No other source of UVA light may be used. Please refer to the Operator's Manual for the INT100 Illuminator. Discard any platelet components not exposed to the complete INT100 illumination process. Tubing components and container ports of the INTERCEPT Blood System for Platelets contain polyvinyl chloride (PVC). Di(2-ethylhexyl)phthalate (DEHP) is known to be released from PVC medical devices, and increased leaching can occur with extended storage or increased surface area contact. Blood components will be in contact with PVC for a brief period of time (approx. 15 minutes) during processing. The risks associated with DEHP released into the blood components must be weighed against the benefits of therapeutic transfusion. PLATELETS: Pulmonary events: Acute Respiratory Distress Syndrome (ARDS) INTERCEPT processed platelets may cause the following adverse reaction: Acute Respiratory Distress Syndrome (ARDS) An increased incidence of ARDS was reported in a randomized trial for recipients of INTERCEPT processed platelets, 5/318 (1.6%), compared to recipients of conventional platelet components (0/327). Monitor patients for signs and symptoms of ARDS.



GLOBAL HEADQUARTERS | 1220 Concord Avenue | Concord, CA US 94520 | 855.835.3523  
[www.cerus.com](http://www.cerus.com) | [www.intercept-usa.com](http://www.intercept-usa.com)

Rx only. See package insert for full prescribing information.

Amicus is a registered trademark of Fenwal Inc. Trima is a registered trademark of Terumo BCT, Inc.